| abstract |
A novel combination comprising a 17α hydroxylase/C17,20 lyase inhibitor, such as (3β)17(pyridinyl)andro5,16adienol or a pharmaceutically acceptable salt or ester thereof, and AKT inhibitors such as N{(1S)2amino1[(3fluorophenyl)methyl]ethyl}5chloro4(4chloro1methyl1Hpyrazol5yl)2thiophenecarboxamide or its pharmaceutically Acceptable salts, and optionally additional antineoplastic agents; pharmaceutical compositions containing them and methods of using such combinations and compositions for the treatment of disorders in which 17α hydroxylase/C17,20 lyase and and/or inhibition of AKT is beneficial, eg in cancer. |